19
Automated Synthesis Module for
Labeling Peptides with Fluorine-18—Lynntech,
Inc., 7607 Eastmark Drive, Suite 102, College
Station, TX 77840-4027;
979-693-0017, http://lynntech.com
Dr. Hariprasad Gali, Principal
Investigator, hari.gali@lynntech.com
Dr. G. Duncan Hitchens, Business
Official, duncan.hitchens@lynntech.com
DOE Grant No. DE-FG02-05ER84288
Amount: $100,000
18F-FDG ([18F]2-deoxy-2-fluoro-D-glucose) is
widely used for the diagnosis, staging, and monitoring of malignancies using
positron emission tomography (PET). However, its accumulation in tissue is not
specific to malignancies only, and also is ineffective for detecting cancers
with no enhanced glucose utilization. Consequently,
there is a great need to develop tumor-selective PET agents. Both higher
target-to-background ratios and rapid blood clearance can often be achieved by
using receptor-avid peptides as targeting vectors, due to their smaller size
and high binding affinities. Unfortunately,
the 18F-labeled peptides are not suitable for clinical use due to
their laborious (multi-step synthesis and purification required) labeling
methods, currently performed manually in sophisticated laboratories by highly
trained personnel. This project will
develop and an automated synthesis module for easy and efficient preparation of
the 18F-labeled peptide-based PET radiopharmaceuticals routinely. Phase I will: (1) optimize system
design in preliminary studies to avoid potential problems and to address safety
issues, (2) develop a first generation prototype design based on the optimized
system design, and (3) fabricate and test the first generation prototype using a
non-radioactive surrogate.
Commercial Applications and Other Benefits as described by the awardee: Positron emission tomography (PET) is currently the fastest growing segment of nuclear medicine due to
its superior sensitivity, spatial resolution, and quantification. Growth should continue with procedure volume
increasing about 35%, reaching 2.1 million procedures by 2010. New PET imaging probes should expand the range of classical indications that
can use PET as a diagnostic tool and also increase the
economical benefits to PET centers.